WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

Its sister company WuXi Biologics rose 4.7%, while WuXi XDC, a contract medical research unit of WuXi Biologics, was up 5.0%. The WuXi companies have come under scrutiny amid tensions between the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Samsung Biologics Logo (PRNewsfoto/Samsung Biologics) "2024 has been a year of steady progress for Samsung Biologics as we expanded collaboration with both pharma and biotech companies ...

Samsung Biologics Logo (PRNewsfoto/Samsung Biologics) "2024 has been a year of steady progress for Samsung Biologics as we expanded collaboration with both pharma and biotech companies, supported by ...

But Korean powerhouse Samsung Biologics has somehow avoided the slide. The company has reported another robust increase in its top line, with a 23% sales boost, from 3.69 trillion Korean won in ...

has accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma. The FDA granted the BLA Priority Review ...

WuXi STA expects to hire about 500 people in the coming years to support Phase 1 of the manufacturing campus. A Chinese pharmaceutical company is moving forward with plans to build a massive $510 ...

The Hong Kong stock market has moved lower in two straight sessions, shedding more than 400 points or 2 percent along the way. The ...